NCT04450732 : A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Treatment<br/>TrialTypeTreatment
Trial

OnePhase One

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Treatment | Breast,Female reproductive organs,Stomach and upper gastrointestinal tract,Urinary systemBladder,Breast,Ovary,Pancreas,Stomach

Trial Overview Read MoreRead more

This phase I trial is testing different doses (amounts) of a new targeted therapy in adults with HER2-positive cancer.
 

This trial is treating patients with advanced HER2-postitive cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors

Commercial Sponsor

GeneQuantum Healthcare (Suzhou) Co., Ltd.

Summary

Eligible patients will be assigned to receive GQ1001, an antibody drug conjugate, intravenously, every 21-Days. GQ1001 will be administered at various doses, starting at 1.2mg/kg, through to 2.4mg/kg, 3.6mg/kg, 4.8mg/kg and 6.0mg/kg.

Recruiting Hospitals Read MoreRead more

Cabrini Education and Research Precinct
Malvern
Li Hoon Lai
lihoonlai@cabrini.com.au
(03) 9508 3421

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next